DPY-30 Activators
DPY-30 Activators represent a specialized category of chemical entities that are designed to selectively enhance the activity of the DPY-30 protein, a core component of the Set1/Mixed Lineage Leukemia (MLL) complexes involved in histone H3 lysine 4 (H3K4) methylation. These activators are characterized by their ability to interact with the protein's functional domains, leading to an upregulation of its associated activity within the chromatin-modifying complex. By doing so, DPY-30 activators can exert a significant effect on the epigenetic regulation mechanisms that DPY-30 is a part of. The mechanisms through which these activators function may include stabilization of the DPY-30 protein, enhancing its interaction with other core components of the MLL complexes, or facilitating the recruitment of these complexes to specific chromatin sites where H3K4 methylation is to be augmented.
The biochemical activation mechanisms by which DPY-30 Activators operate are grounded in the modulation of the intricate network of protein-protein interactions and the catalytic processes governing epigenetic modifications. These activators may influence the DPY-30 protein's ability to contribute to the assembly and stabilization of the multiprotein MLL complex, thereby enhancing its histone methyltransferase activity. The activation process does not merely increase the quantity of DPY-30 available but rather enhances its functional efficacy in the context of histone methylation. Consequently, DPY-30 Activators indirectly influence gene expression patterns by modulating the epigenetic landscape, impacting cellular differentiation, and development processes governed by the H3K4 methylation status. These activators are crucial in understanding the regulation of gene transcription and the dynamic nature of chromatin structure, which are pivotal in maintaining cellular identity and function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels, which in turn activates PKA. PKA can phosphorylate various proteins, potentially enhancing the activity of DPY-30 by promoting its association with complexes that regulate gene expression. | ||||||
Ademetionine | 29908-03-0 | sc-278677 sc-278677A | 100 mg 1 g | $180.00 $655.00 | 2 | |
S-adenosylmethionine serves as a methyl donor in numerous methylation reactions catalyzed by methyltransferases. As DPY-30 is known to be part of the Set1/COMPASS complex, which methylates histone H3, this compound could enhance DPY-30's role in histone methylation and thus gene regulation. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is incorporated into RNA and DNA and inhibits DNA methyltransferases, leading to hypomethylation of DNA. This can result in increased expression of certain genes, potentially enhancing the activity of DPY-30 in gene regulation via chromatin remodeling. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, results in hyperacetylated histone tails, which can lead to a more open chromatin structure. DPY-30, being involved in chromatin organization, might have its functional role enhanced due to changes in chromatin state. | ||||||
Nicotinamide | 98-92-0 | sc-208096 sc-208096A sc-208096B sc-208096C | 100 g 250 g 1 kg 5 kg | $43.00 $65.00 $200.00 $815.00 | 6 | |
Nicotinamide inhibits sirtuins, which are a class of histone deacetylases. This inhibition can lead to changes in chromatin structure, potentially enhancing DPY-30's role in transcriptional regulation due to the altered histone acetylation landscape. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Epigallocatechin gallate inhibits DNA methyltransferases, which could lead to hypomethylated promoters and an enhanced expression of certain genes. This may indirectly enhance the activity of DPY-30 in gene regulation. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
SAHA is a histone deacetylase inhibitor that leads to increased acetylation of histones, potentially enhancing DPY-30's role in the regulation of gene expression by altering chromatin accessibility. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $79.00 $300.00 | 32 | |
Parthenolide inhibits NF-kB pathway, which may lead to changes in gene expression profiles. These changes could indirectly enhance DPY-30's involvement in chromatin modification and transcriptional regulation. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
Sodium butyrate is a histone deacetylase inhibitor, which can lead to a more open chromatin state and potentially enhance DPY-30's activity by increasing transcription of genes whose products are involved in chromatin remodeling. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol has multiple targets, one of which includes inhibiting DNA methyltransferases. This action could lead to changes in gene expression patterns, indirectly enhancing DPY-30's functional role in chromatin organization and gene regulation. | ||||||